Impact of body mass index on overall survival in patients with metastatic breast cancer

Saleh, Khalil; Carton, Matthieu; Dièras, Véronique; Heudel, Pierre; Brain, Étienne; Mailliez, Audrey; Patsouris, Anne; Mouret-Reynier, Marie-Ange; Gonçalvès, Anthony; Ferrero, Jean Marc; Petit, Thierry; Emile, George; Uwer, Lionel; Debled, Marc; Jouannaud, Christelle; Ladoire, Sylvain; Leheurteur, Marianne; Cottu, Paul; Veron, Lucie; Savignoni, Alexia; Courtinard, Coralie; Robain, Mathieu; Delaloge, Suzette; Deluche, Élise

doi:10.1016/j.breast.2020.11.014

Cited by 26 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To our knowledge, advances in cancer care along with the availability of Obesity, which is represented by BMI ≥ 25 for the Asian population, did not increase the recurrence rate or impair the survival rate of patients with breast cancer. Our results showed concordance with Saleh et al (2021) and contrasted with a meta-analysis of 82 follow-up studies (Chan et al, 2014). Most studies showed a negative effect of overweight and obesity on the survival of breast cancer in a U or J shape, with underweight and obesity associated with all-cause mortality, which could not be shown from our data.…”

Section: Discussionsupporting

confidence: 81%

The Association between Abdominal Obesity, Metabolic Syndrome and Survival Outcomes in Patients with Breast Cancer

Taroeno-Hariadi

Putra

Ariesta

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Obesity and metabolic syndrome (MetS) have been linked to the risk of developing certain cancers. This study aimed to analyze the association between obesity markers, MetS and survival outcomes of patients with breast cancer. Methods: This study retrospectively investigated patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-), nonmetastatic breast cancer diagnosed between January 2010 and December 2019. Data on clinical conditions, body mass index (BMI), waist-to-hip ratio (WHR), MetS, time of metastasis and death were collected. Results: A total of 223 breast cancer patient records were eligible for analysis. Obesity (BMI ≥ 25) was found in 38.1% of cases. Abdominal obesity measured as WHR ≥ 0.85 was found in 48.9%. Metabolic syndrome was detected in 56.1% of patients and was associated with older age (OR = 2.196, p = 0.005), postmenopausal status (OR = 2.585, p = 0.001), obesity (OR = 5.684, p = 0.001) and abdominal obesity (OR = 2.612, p = 0.001). Obesity was not associated with poor disease-free survival (DFS) or overall survival (OS), while abdominal obesity was modestly associated with poor DFS (HR = 1.539, p = 0.083) and OS (HR = 3.117; p = 0.019). Multivariate analysis revealed that WHR ≥ 0.85 was independently associated with unfavorable DFS (HR = 1.907, p = 0.027). Patients with MetS had a similar survival rate to those with normal metabolism. Conclusion: In Indonesian women with HR+/HER2-breast cancers, obesity and MetS were not associated with poor survival outcomes. The abdominal obesity marker (WHR) was more accurate in predicting unfavorable DFS.

show abstract

Section: Discussionsupporting

confidence: 81%

The Association between Abdominal Obesity, Metabolic Syndrome and Survival Outcomes in Patients with Breast Cancer

Taroeno-Hariadi

Putra

Ariesta

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…The meta‐analyses included 101 publications reporting postdiagnosis BMI (assessed from at‐diagnosis to on average 5.8 years postdiagnosis), waist circumference (at‐diagnosis to 7.9 years postdiagnosis), waist‐to‐hip ratio (at‐diagnosis to 2.5 years postdiagnosis) and pre‐ to postdiagnosis weight gain or loss (from 1 year before to 1 year or more after diagnosis) 27,39‐138 . In addition, 119 publications were descriptively synthesized…”

Section: Resultsmentioning

confidence: 99%

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Chan

Vieira

Abar

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Previous evidence on postdiagnosis body fatness and mortality after breast cancer was graded as limited-suggestive. To evaluate the evidence on body mass index (BMI), waist circumference, waist-hip-ratio and weight change in relation to breast cancer prognosis, an updated systematic review was conducted. PubMed and Embase were searched for relevant studies published up to 31 October, 2021. Random-effects meta-analyses were conducted to estimate summary relative risks (RRs).The evidence was judged by an independent Expert Panel using pre-defined grading criteria. One randomized controlled trial and 225 observational studies were reviewed (220 publications). There was strong evidence (likelihood of causality: probable) that higher postdiagnosis BMI was associated with increased all-cause mortality (64 studies, 32 507 deaths), breast cancer-specific mortality (39 studies, 14 106 deaths) and second primary breast cancer (11 studies, 5248 events). The respective summary RRs and 95% confidence intervals per 5 kg/m 2 BMI were 1.

show abstract

“…Various studies suggested the association between BMI and cancer mortality [36][37][38] . Accordingly, overweight patients have the lowest odds of cancer death than the rest.…”

Section: The Benefit Of Vitamin D Is Correlated With the Bmi Of The P...mentioning

confidence: 99%

Vitamin D supplementation improves the prognosis of patients with colorectal cancer liver metastases

Rada

Krzywon

Kapelanski-Lamoureux

et al. 2022

Preprint

View full text Add to dashboard Cite

Colorectal cancer liver metastasis (CRCLM) is one of the deadliest cancers. CRCLM tumours have two distinct histopathological growth patterns (HGPs) including desmoplastic HGP (DHGP) and replacement HGP (RHGP). The DHGP tumours are angiogenic, while their RHGP counterparts are vessel co-opting. The patients with DHGP tumours have a better response to anti-angiogenic agents and chemotherapy, as well as the prognosis. To determine the influence of vitamin D supplementation in CRCLM, we analyzed the HGPs and the 5-year OS of CRCLM patients (n=106). Interestingly, we found an inverse correlation between vitamin D supplementation and the presence of RHGP tumours in CRCLM patients. Additionally, the 5-year OS of the patients that administered vitamin D was significantly higher. The cancer cells in RHGP lesions are characterized by direct contact with the hepatocytes, and this phenomenon enhances the motility of the cancer cells and facilitates their infiltration through liver parenchyma to co-opt the pre-existing vessels. Significantly, our in vitro data demonstrated the downregulation of motility markers in the co-cultured cancer cells with hepatocytes upon exposure to vitamin D. Altogether, this study highlights the role of vitamin D in CRCLM and provides a rationale to investigate the contribution of vitamin D supplementation to the prognosis of CRCLM patients

show abstract

Impact of body mass index on overall survival in patients with metastatic breast cancer

Cited by 26 publications

References 41 publications

The Association between Abdominal Obesity, Metabolic Syndrome and Survival Outcomes in Patients with Breast Cancer

The Association between Abdominal Obesity, Metabolic Syndrome and Survival Outcomes in Patients with Breast Cancer

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Vitamin D supplementation improves the prognosis of patients with colorectal cancer liver metastases

Contact Info

Product

Resources

About